

# William Chey

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4590236/publications.pdf>

Version: 2024-02-01

86  
papers

4,555  
citations

109321  
35  
h-index

102487  
66  
g-index

86  
all docs

86  
docs citations

86  
times ranked

3747  
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome – results of two randomized, placebo-controlled studies. <i>Alimentary Pharmacology and Therapeutics</i> , 2009, 29, 329-341.	3.7	344
2	Comparison of gastric emptying of a nondigestible capsule to a radio-labelled meal in healthy and gastroparetic subjects. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 27, 186-196.	3.7	293
3	Type of pain, pain-associated complications, quality of life, disability and resource utilisation in chronic pancreatitis: a prospective cohort study. <i>Cut</i> , 2011, 60, 77-84.	12.1	261
4	Systematic review: cardiovascular safety profile of 5-HT <sub>4</sub> agonists developed for gastrointestinal disorders. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 745-767.	3.7	236
5	Can endoscopic ultrasound or magnetic resonance cholangiopancreatography replace ERCP in patients with suspected biliary disease? A prospective trial and cost analysis. <i>American Journal of Gastroenterology</i> , 2001, 96, 2900-2904.	0.4	211
6	A Randomized Placebo-Controlled Phase IIb Trial of A3309, A Bile Acid Transporter Inhibitor, for Chronic Idiopathic Constipation. <i>American Journal of Gastroenterology</i> , 2011, 106, 1803-1812.	0.4	156
7	The Yield of Colonoscopy in Patients With Non-Constipated Irritable Bowel Syndrome: Results From a Prospective, Controlled US Trial. <i>American Journal of Gastroenterology</i> , 2010, 105, 859-865.	0.4	148
8	The assessment of regional gut transit times in healthy controls and patients with gastroparesis using wireless motility technology. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 31, 313-322.	3.7	123
9	Pure cut electrocautery current for sphincterotomy causes less post-procedure pancreatitis than blended current. <i>Gastrointestinal Endoscopy</i> , 1998, 47, 149-153.	1.0	118
10	Randomised clinical trials: linaclotide phase 3 studies in IBS – a prespecified further analysis based on European Medicines Agency-specified endpoints. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 49-61.	3.7	115
11	Safety and patient outcomes with lubiprostone for up to 52 weeks in patients with irritable bowel syndrome with constipation. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 587-599.	3.7	105
12	Randomised clinical trial: the long-term safety and tolerability of naloxegol in patients with pain and opioid-induced constipation. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 771-779.	3.7	102
13	The gut microbiome and irritable bowel syndrome. <i>F1000Research</i> , 2018, 7, 1029.	1.6	94
14	Measuring irritable bowel syndrome patient-reported outcomes with an abdominal pain numeric rating scale. <i>Alimentary Pharmacology and Therapeutics</i> , 2009, 30, 1159-1170.	3.7	93
15	The influence of co-morbid IBS and psychological distress on outcomes and quality of life following PPI therapy in patients with gastro-oesophageal reflux disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 27, 473-482.	3.7	91
16	Motility of the antroduodenum in healthy and gastroparetics characterized by wireless motility capsule. <i>Neurogastroenterology and Motility</i> , 2010, 22, 527-33, e117.	3.0	91
17	Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double-blind, placebo-controlled trials. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 1161-1168.	3.7	90
18	Clinical trial: the effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non-erosive reflux disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2009, 29, 1261-1272.	3.7	82

#	ARTICLE	IF	CITATIONS
19	A Systematic Review of the Effects of Polyols on Gastrointestinal Health and Irritable Bowel Syndrome. <i>Advances in Nutrition</i> , 2017, 8, 587-596.	6.4	81
20	Review article: current and emerging therapies for functional dyspepsia. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 24, 475-492.	3.7	71
21	Lansoprazole and ranitidine affect the accuracy of the 14C-urea breath test by a pH-dependent mechanism. <i>American Journal of Gastroenterology</i> , 1997, 92, 446-50.	0.4	70
22	A biomarker panel and psychological morbidity differentiates the irritable bowel syndrome from health and provides novel pathophysiological leads. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 426-437.	3.7	65
23	Measuring symptoms in the irritable bowel syndrome: development of a framework for clinical trials. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 32, 1275-1291.	3.7	64
24	Irritable bowel syndrome - an evidence-based approach to diagnosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2004, 19, 1235-1245.	3.7	57
25	Cilansetron: a new serotonergic agent for the irritable bowel syndrome with diarrhoea. <i>Expert Opinion on Investigational Drugs</i> , 2005, 14, 185-193.	4.1	56
26	Treatment patterns and symptom control in patients with GERD: US community-based survey. <i>Current Medical Research and Opinion</i> , 2009, 25, 1869-1878.	1.9	56
27	Reappraisal of non-invasive management strategies for uninvestigated dyspepsia: a cost-minimization analysis. <i>Alimentary Pharmacology and Therapeutics</i> , 2002, 16, 1491-1501.	3.7	51
28	Patient and Physician Satisfaction with Proton Pump Inhibitors (PPIs): Are There Opportunities for Improvement?. <i>Digestive Diseases and Sciences</i> , 2010, 55, 3415-3422.	2.3	50
29	Hyperglycemia alters perception of rectal distention and blunts the rectoanal inhibitory reflex in healthy volunteers. <i>Gastroenterology</i> , 1995, 108, 1700-1708.	1.3	49
30	Prolonged effect of omeprazole on the 14C-urea breath test. <i>American Journal of Gastroenterology</i> , 1996, 91, 89-92.	0.4	49
31	Oesophageal hypersensitivity is associated with features of psychiatric disorders and the irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 26, 443-452.	3.7	48
32	Effects of baseline abdominal pain and bloating on response to lubiprostone in patients with irritable bowel syndrome with constipation. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 1114-1122.	3.7	47
33	The Impact of a 4-Week Low-FODMAP and mNICE Diet on Nutrient Intake in a Sample of US Adults with Irritable Bowel Syndrome with Diarrhea. <i>Journal of the Academy of Nutrition and Dietetics</i> , 2020, 120, 641-649.	0.8	42
34	Computer-Generated Vs. Physician-Documented History of Present Illness (HPI): Results of a Blinded Comparison. <i>American Journal of Gastroenterology</i> , 2015, 110, 170-179.	0.4	41
35	Factors associated with quality of life among women with fecal incontinence. <i>International Urogynecology Journal</i> , 2013, 24, 493-499.	1.4	37
36	Analysis of Nausea in Clinical Studies of Lubiprostone for the Treatment of Constipation Disorders. <i>Digestive Diseases and Sciences</i> , 2017, 62, 3568-3578.	2.3	36

#	ARTICLE	IF	CITATIONS
37	Intragastric Acidification Reduces The Occurrence of False-Negative Urea Breath Test Results in Patients Taking A Proton Pump Inhibitor. American Journal of Gastroenterology, 2001, 96, 1028-1032.	0.4	34
38	Lansoprazole and Esomeprazole in Symptomatic GERD. Clinical Drug Investigation, 2003, 23, 69-84.	2.2	33
39	Accurate Diagnosis of Helicobacter Pylori. Gastroenterology Clinics of North America, 2000, 29, 895-902.	2.2	31
40	Factors Associated with Symptom Severity in Women Presenting with Fecal Incontinence. Diseases of the Colon and Rectum, 2013, 56, 97-102.	1.3	31
41	Uninvestigated dyspepsia and non- <i>Helicobacter pylori</i> eradication and antisecretory therapy. Alimentary Pharmacology and Therapeutics, 2004, 19, 1-8.	3.7	30
42	Characterizing abdominal pain in IBS: guidance for study inclusion criteria, outcome measurement and clinical practice. Alimentary Pharmacology and Therapeutics, 2010, 32, 1192-1202.	3.7	30
43	Maintenance oral pantoprazole therapy is effective for patients with Zollinger-Ellison syndrome and idiopathic hypersecretion. American Journal of Gastroenterology, 2003, 98, 301-307.	0.4	29
44	Dietary Renaissance in IBS: Has Food Replaced Medications as a Primary Treatment Strategy?. Current Treatment Options in Gastroenterology, 2014, 12, 424-440.	0.8	28
45	Gastric Emptying Characteristics of a Novel 13C-Octanoate-labeled Muffin Meal. Journal of Clinical Gastroenterology, 2001, 32, 394-399.	2.2	27
46	Angiodysplasia and von willebrand's disease type IIB treated with estrogen/progesterone therapy. American Journal of Hematology, 1992, 41, 276-279.	4.1	26
47	Routine droperidol pre-medication improves sedation for ERCP. Gastrointestinal Endoscopy, 2000, 52, 362-366.	1.0	26
48	Effect of meal size and test duration on gastric emptying and gastric myoelectrical activity as determined with simultaneous [13C]octanoate breath test and electrogastrography in normal subjects using a muffin meal. Digestive Diseases and Sciences, 2001, 46, 2643-2650.	2.3	26
49	Fermented Fiber Supplements Are No Better Than Placebo for a Laxative Effect. Digestive Diseases and Sciences, 2016, 61, 3140-3146.	2.3	25
50	Early response predicts a sustained response to eluxadoline in patients with irritable bowel syndrome with diarrhoea in two Phase 3 studies. Alimentary Pharmacology and Therapeutics, 2017, 45, 1319-1328.	3.7	25
51	A Comparison of Three Fingerstick, Whole Blood Antibody Tests for Helicobacter Pylori Infection: A United States, Multicenter Trial. American Journal of Gastroenterology, 1999, 94, 1512-1516.	0.4	24
52	Noninvasive Helicobacter pylori Testing for the "Test-and-Treat" Strategy. Archives of Internal Medicine, 2001, 161, 2129.	3.8	23
53	Advances in the management of irritable bowel syndrome. Current Gastroenterology Reports, 2003, 5, 468-475.	2.5	22
54	Symptom status and the desire for Helicobacter pylori confirmatory testing after eradication therapy in patients with peptic ulcer disease. American Journal of Medicine, 1999, 107, 133-136.	1.5	21

#	ARTICLE	IF	CITATIONS
55	Mechanism of action and therapeutic benefit of rifaximin in patients with irritable bowel syndrome: a narrative review. Therapeutic Advances in Gastroenterology, 2020, 13, 175628481989753.	3.2	21
56	Low- versus high-dose azithromycin triple therapy for Helicobacter pylori infection. Alimentary Pharmacology and Therapeutics, 1998, 12, 1263-1267.	3.7	20
57	The 13C-Urea Blood Test Accurately Detects Active Helicobacter Pylori Infection: A United States, Multicenter Trial. American Journal of Gastroenterology, 1999, 94, 1522-1524.	0.4	20
58	Effect of acute acoustic stress on anorectal function and sensation in healthy humans <sup>1</sup> . Neurogastroenterology and Motility, 2005, 17, 222-228.	3.0	19
59	Appropriate Timing of The 14C-Urea Breath Test To Establish Eradication of Helicobacter Pylori Infection. American Journal of Gastroenterology, 2000, 95, 1171-1174.	0.4	18
60	Changing perceptions and practices regarding aspirin, nonsteroidal anti-inflammatory drugs, and cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs among US primary care providers. Alimentary Pharmacology and Therapeutics, 2008, 28, 1249-1258.	3.7	18
61	Long-Term Tegaserod Treatment for Dysmotility-like Functional Dyspepsia: Results of Two Identical 1-year Cohort Studies. Digestive Diseases and Sciences, 2010, 55, 684-697.	2.3	18
62	Octreotide reduces perception of rectal electrical stimulation by spinal afferent pathway inhibition. American Journal of Physiology - Renal Physiology, 1995, 269, G821-G826.	3.4	16
63	Irritable bowel syndrome: Update on colonic neuromuscular dysfunction and treatment. Current Gastroenterology Reports, 2006, 8, 273-281.	2.5	15
64	Recent developments in the therapy of irritable bowel syndrome. Expert Opinion on Investigational Drugs, 2008, 17, 117-130.	4.1	15
65	Omeprazole or ranitidine bismuth citrate triple therapy to treat Helicobacter pylori infection: a randomized, controlled trial in Vietnamese patients with duodenal ulcer. Alimentary Pharmacology and Therapeutics, 2000, 14, 97-101.	3.7	14
66	Primary care physician perceptions of non-steroidal anti-inflammatory drug and aspirin-associated toxicity: results of a national survey. Alimentary Pharmacology and Therapeutics, 2006, 23, 655-668.	3.7	14
67	A clinician's guide to managing Helicobacter pylori infection.. Cleveland Clinic Journal of Medicine, 2005, 72, 109-110.	1.3	13
68	Evaluation of the Ez-HBT Helicobacter blood test to establish Helicobacter pylori eradication. Alimentary Pharmacology and Therapeutics, 2005, 22, 875-880.	3.7	12
69	Lubiprostone for chronic idiopathic constipation and irritable bowel syndrome with constipation. Expert Review of Gastroenterology and Hepatology, 2008, 2, 497-508.	3.0	11
70	Proton pump inhibitors and the urea breath test: how long is long enough?. American Journal of Gastroenterology, 1997, 92, 720-1.	0.4	11
71	The Chemtrak Hp Chek Fingerstick Whole Blood Serology Test for the Detection of Helicobacter pylori Infection. American Journal of Gastroenterology, 1998, 93, 16-19.	0.4	10
72	The channel occlusion technique: a novel method of retrieving polyps following snare resection. American Journal of Gastroenterology, 2000, 95, 1608-1609.	0.4	10

#	ARTICLE	IF	CITATIONS
73	Review article: tegaserod - the global experience. <i>Alimentary Pharmacology and Therapeutics</i> , 2004, 20, 15-19.	3.7	10
74	Endoscopy of the esophagus in gastroesophageal reflux disease: are we losing sight of symptoms? Another perspective. <i>Ecological Management and Restoration</i> , 2009, 22, 461-466.	0.4	8
75	Severe Hypertension Induced by the Long-Acting Somatostatin Analogue Sandostatin LAR in a Patient with Diabetic Autonomic Neuropathy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 943-946.	3.6	8
76	Bismuth subsalicylate instead of metronidazole with lansoprazole and clarithromycin for <i>Helicobacter pylori</i> infection: a randomized trial. <i>American Journal of Gastroenterology</i> , 1997, 92, 1483-6.	0.4	8
77	Targeting bile acids in the treatment of constipation. <i>Expert Review of Gastroenterology and Hepatology</i> , 2011, 5, 657-659.	3.0	6
78	Editorial: recurrence of <i>Helicobacter pylori</i> infection“still the same after all these years”. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 131-132.	3.7	5
79	Pneumatosis Coli and Colonic Intussusception. <i>New England Journal of Medicine</i> , 2001, 345, 964-964.	27.0	4
80	One-Week Therapy for <i>Helicobacter pylori</i> . <i>Journal of Clinical Gastroenterology</i> , 1996, 23, 170-173.	2.2	4
81	Possible Nizatidine-Induced Subfulminant Hepatic Failure. <i>Journal of Clinical Gastroenterology</i> , 1995, 20, 164-167.	2.2	3
82	Radar plots: A novel modality for displaying disparate data on the efficacy of eluxadoline for the treatment of irritable bowel syndrome with diarrhea. <i>Neurogastroenterology and Motility</i> , 2018, 30, e13331.	3.0	3
83	Integrated care for disorders of gut“brain interaction. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 876-877.	8.1	3
84	Preliminary development and validation of the Patient“Physician Relationship Scale for physicians for disorders of gut“brain interaction. <i>Neurogastroenterology and Motility</i> , 2021, 33, e13976.	3.0	3
85	Review: prokinetics, histamine H2 receptor antagonists, antimuscarinics, and proton pump inhibitors improve global symptoms in non-ulcer dyspepsia. <i>Evidence-Based Medicine</i> , 2007, 12, 79-79.	0.6	1
86	Implications for treatment: pH, <i>Helicobacter pylori</i> or alternative approaches?. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 21, 17-18.	3.7	0